Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

Abstract Monoclonal IgG antibodies constitute the fastest growing class of therapeutics. Thus, there is an intense interest to design more potent antibody formats, where long plasma half-life is a commercially competitive differentiator affecting dosing, frequency of administration and thereby poten...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Stian Foss, Siri A. Sakya, Leire Aguinagalde, Marta Lustig, Jutamas Shaughnessy, Ana Rita Cruz, Lisette Scheepmaker, Line Mathiesen, Fulgencio Ruso-Julve, Aina Karen Anthi, Torleif Tollefsrud Gjølberg, Simone Mester, Malin Bern, Mitchell Evers, Diane B. Bratlie, Terje E. Michaelsen, Tilman Schlothauer, Devin Sok, Jayanta Bhattacharya, Jeanette Leusen, Thomas Valerius, Sanjay Ram, Suzan H. M. Rooijakkers, Inger Sandlie, Jan Terje Andersen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-03-01
coleção:	Nature Communications
Acesso em linha:	https://doi.org/10.1038/s41467-024-46321-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!